A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
NCT05950334 — Relapsed/Refractory B-Cell Lymphoma
Status: Recruiting
http://inclinicaltrials.com/relapsed-refractory-b-cell-lymphoma/NCT05950334/
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma：a Single-Arm, Open Lable， Multicenter Clinical Trial（LINCH Study）
This phase Ib/II, single arm, open label, multicenter study is conducted to evaluate the efficacy and safety of linperlisib in combination with CHOP for newly diagnosed PTCL patients, and explore the reasonable dosage of linperlisib when combined with CHOP regimen.
NCT05949944 — Peripheral T-cell Lymphoma
Status: Recruiting
http://inclinicaltrials.com/peripheral-t-cell-lymphoma/NCT05949944/
A Randomized, Open, Multicenter Phase II Clinical Trial of Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma (PENAHL Study)
This study is conducted to evaluate the safety and efficiency of Penpulimab combined with AVD in patients with newly- diagnosed advanced classic Hodgkin lymphoma.
NCT05949931 — Classic Hodgkin Lymphoma
Status: Not yet recruiting
http://inclinicaltrials.com/classic-hodgkin-lymphoma/NCT05949931/
Phase I/II Study of CD70 Targeted CAR-T Cell Treatment in CD70 Positive Relapsed/Refractory Lymphoma
In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive Relapsed/Refractory Lymphoma . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).
NCT05948033 — Lymphoma
Status: Recruiting
http://inclinicaltrials.com/lymphoma/NCT05948033/
Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
NCT05940272 — Lymphoma
Status: Recruiting
http://inclinicaltrials.com/lymphoma/NCT05940272/
Prospective Single-arm, Single-center Clinical Study of Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Regimen in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma
This is a prospective, single-arm, single-center clinical study. This clinical study aims to explore the efficacy and safety of the ZPR（Zanubrutinib, Polatuzumab vedotin and Rituximab）regimen in elderly patients with treatment-naive diffuse large B-cell lymphoma.
NCT05940064 — Diffuse Large B Cell Lymphoma
Status: Recruiting
http://inclinicaltrials.com/diffuse-large-b-cell-lymphoma/NCT05940064/
Prospective Single-arm, Single-center Clinical Study of Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Regimen in Relapsed/Refractory Patients With Diffuse Large B-cell Lymphoma
This is a prospective, single-arm, single-center clinical study. This clinical study aims to explore the efficacy and safety of the ZPR（Zanubrutinib, Polatuzumab vedotin and Rituximab）regimen in the treatment of patients with relapsed and refractory diffuse large B-cell lymphoma.
NCT05940051 — Diffuse Large B Cell Lymphoma
Status: Recruiting
http://inclinicaltrials.com/diffuse-large-b-cell-lymphoma/NCT05940051/
The Impact of Inspiratory Muscle Strength Training and Personalized Exercise Prescription on Metabolism, Cardiovascular Function, and Cardiorespiratory Fitness in Lymphoma Survivors
High-resistance inspiratory muscle strength training (IMST) is a time-efficient (~5 minutes/day) form of exercise that employs an affordable, handheld device which impedes inspiratory breathing to train the diaphragm and accessory respiratory muscles and has demonstrated improvements in both cardiovascular health (9 mmHg reduction in systolic blood pressure, 45% improvement in vascular endothelial function) and improve exercise tolerance (12% increase in treadmill exercise time) in generally healthy midlife/older adults. Therefore, this approach may circumvent preventative hurdles to exercise, and augment the effects of exercise for capable survivors.
NCT05938127 — Hodgkin Lymphoma
Status: Recruiting
http://inclinicaltrials.com/hodgkin-lymphoma/NCT05938127/
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.
NCT05934838 — Mantle Cell Lymphoma
Status: Recruiting
http://inclinicaltrials.com/mantle-cell-lymphoma/NCT05934838/
A Phase Ib/II, Multicentre, Open-label Study to Assess the Efficacy, Safety/ Tolerability and Pharmacokinetic of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma
NCT05934513 — Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Status: Recruiting
http://inclinicaltrials.com/relapsed-or-refractory-peripheral-t-cell-lymphoma-ptcl/NCT05934513/